A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device

Osteoarthritis of the Knee Clinical Trial

Official title:

A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01704157
• Other study ID #: MYO-0601
• Secondary ID: Pain-OA
• Status: Completed
• Phase: N/A
• Start date: September 2012
• Est. completion date: July 2013

Study information

• Verified date: January 2024
• Source: Pacira Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III device for temporary relief of pain.

Description:

Over 100 million patients in the United States suffer from chronic pain. Chronic pain conditions are often debilitating, taking a toll on a patient's physical and mental welfare. Though a variety of pain management techniques currently exist, the most common nonsurgical options provide slow-acting and/or short-term relief. Medication, often in the form of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with an array of side effects such as nausea and vomiting. Medication also presents the possibility of more serious effects such as increased risk of heart attack and stroke, and tolerance or dependency issues. Surgical strategies tend to be reserved for more severe cases and are limited by the risks and complications typically associated with surgery including bleeding, bruising, scarring, and infection. A nonsurgical, minimally invasive, long-lasting approach to chronic pain management is desirable.

The Cryo-Touch III is a pain management device developed for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled moderately low temperature conditions can alter tissue function. The therapy treats nerves with low temperatures via a cold probe in the form of an assembly of small diameter needles, creating a highly localized treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling.

Though studies have proven efficacious in targeting motor nerves, the device's effect on sensory nerves has yet to have been investigated in the clinical setting. The goal of the study described herein is to evaluate the degree and duration of effect of the Cryo-Touch III in reducing chronic pain by targeting sensory nerves.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: July 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, 18 years of age and older.

• Participants must meet American College of Rheumatology (ACR) criteria for osteoarthritis of the knee (unilateral or bilateral). Clinical criteria includes knee pain and at least three of the following 6 criteria: 50 years of age or older, stiffness lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, and/or no warmth to the touch.

• Any medications (prescription and/or over-the counter) must be maintained on a stable schedule for = 2 weeks prior to treatment. No washout period is allowed.

• An average Visual Analog Scale (VAS) for pain = 4 over the last 30 days.

• Subject is willing and able to give written informed consent.

• Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study.

• Subject is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.

Exclusion Criteria:

• A partial or full knee replacement (in the treated knee).

• Any use of systemic injections (in any area) within the last 6 months.

• Current enrollment in an investigational drug or a device study that specifically targets pain treatment.

• Any additional diagnosis that in the opinion of the investigator may directly contribute to knee pain.

• Any concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bones disease, gout, active infection, etc.).

• Any clotting disorder and/or has used an anticoagulant (e.g., warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the device.

• Allergy or intolerance to lidocaine.

• Any local skin condition at the treatment site that in the investigator's opinion would adversely affect treatment or outcomes.

• Any chronic medical condition that in the investigator's opinion would prevent adequate participation.

• Any chronic medication use (prescription, over-the-counter, etc.) that in the investigator's opinion would affect study participation or subject safety.

• For any reason, in the opinion of the investigator, the subject may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, any related knee injury due to a worker's compensation claim, etc.).

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis of the Knee
• Osteoarthritis, Knee

Intervention

Device:
• Cryo-Touch III
Study treatment at Day 0.

Locations

Country	Name	City	State
United States	Injury Care Medical Center	Boise	Idaho
United States	Neurovations	Napa	California

Sponsors (1)

Lead Sponsor	Collaborator
Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Improvement in VAS Pain Score From Baseline to Day 7	Visual Analog Scale(VAS), where a higher score indicates greater intensity; 0= no pain, 10=worst pain	Baseline to Day 7
Primary	Improvement in WOMAC Index From Baseline to Day 7	The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scale.; A tri-dimensional, disease-specific, patient-reported outcome measure. Consists of 24 questions: 5 pain, 2 stiffness and 17 function. Each category contains a set of questions rated by the Subject on a 0-10 scale; The highest possible score was 50 for pain, 20 for stiffness and 170 for function, based on the 0-10 scale used to assess each question.; The total score range is 0 to 240 with higher scores correlating to worse outcomes.	Baseline to Day 7
Secondary	Number of Participants Who Experienced Continued Treatment Effect at Each Time Point	Subjects were asked to report whether they experienced continued treatment effect at the timepoints indicated.	Visit 3 (Day 7), Visit 4 (Day 30), Visit 5 (Day 56)